<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122780">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02018172</url>
  </required_header>
  <id_info>
    <org_study_id>000122</org_study_id>
    <nct_id>NCT02018172</nct_id>
  </id_info>
  <brief_title>Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device</brief_title>
  <acronym>ZOMAXEPT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to collect long-term data on the treatment adherence and patient's
      acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in
      patients with a growth hormone deficiency or Turner's syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of overall treatment adherence</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ratio between actual duration of administration and total duration recommended by physician</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Turner's Syndrome</condition>
  <arm_group>
    <arm_group_label>Zomacton® treatment with Zomajet® Vision X device</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <arm_group_label>Zomacton® treatment with Zomajet® Vision X device</arm_group_label>
    <other_name>Zomacton®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a growth hormone deficiency or Turner's syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with growth hormone deficiency,

               1. Diagnosis of growth hormone deficiency proven by appropriate        exploration

               2. Size ≤ -2 Standard Deviation (SD) according to the French references

               3. Growth velocity in the previous year inferior to the normal for age
                  (-1SD) or &lt; 4cm/year

          -  Growth deficiency due to Turner's syndrome

               1. Turner's syndrome confirmed by a karyotype

               2. Patient's size ≤ -2 SD according to the French references

               3. Bone age &lt; 12 years

          -  Patient who require a minimum of 18 months of treatment.

        Exclusion Criteria:

          -  There are no exclusion criteria except the contraindication for Zomacton® 10 mg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>There may be other sites in this country</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital des Enfants, CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
